Research Topics
Genomes and Genes
Species | Michael F PressSummaryAffiliation: University of Southern California Country: USA Publications
| Collaborators
|
Detail Information
Publications
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomasM F Press
Norris Comprehensive Cancer Center and Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 15:2894-904. 1997....
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III studyRichard S Finn
Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
J Clin Oncol 27:5552-8. 2009..We examined the prognostic and predictive role of HER2 ECD in a randomized trial of paclitaxel with placebo or lapatinib in women with HER2-negative or -unknown breast cancer...- HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancerMichael F Press
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
Clin Cancer Res 14:7861-70. 2008..Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy... - A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten
Department of Medicine, University of California, Los Angeles, CA, USA
Clin Breast Cancer 9:16-22. 2009..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer... 
Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic CohortChristopher A Haiman
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
BMC Cancer 9:43. 2009....- Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trialsMichael F Press
Women's Cancers Program, Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 89195, USA
Clin Cancer Res 11:6598-607. 2005.... - A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancerChristopher A Haiman
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
Nat Genet 43:1210-4. 2011..25, P = 1.1 × 10(-9)), particularly in younger women (<50 years of age) (OR = 1.48, P = 1.9 × 10(-9)). Our results identify a genetic locus associated with estrogen receptor negative breast cancer subtypes in multiple populations... - Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American womenVeronica Wendy Setiawan
Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Cancer Genet Cytogenet 181:16-9. 2008..18, 95% CI = 0.76-1.82, P = 0.46). Our results do not support the hypothesis that the mtDNA G10398A polymorphism is, as has previously been reported, a marker of breast cancer risk in African Americans... - A genome-wide association study of breast cancer in women of African ancestryFang Chen
Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Hum Genet 132:39-48. 2013..Identification of novel risk variants for breast cancer in women of African ancestry will demand testing of a substantially larger set of markers from stage 1 in a larger replication sample... - Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerationsGuido Sauter
Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
J Clin Oncol 27:1323-33. 2009..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies... - Serum organochlorines and breast cancer: a case-control study among African-American womenNicole M Gatto
Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, USC Norris Comprehensive Center, 1441 Eastlake Avenue, Room 4449, Los Angeles, CA 90033, USA
Cancer Causes Control 18:29-39. 2007..This study, the largest study of African-American women to date, does not support a role of DDE and total PCBs in breast cancer risk at the levels measured... - Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in Richard S Finn
Geffen School of Medicine at University of California, Los Angeles, CA, USA
J Clin Oncol 27:3908-15. 2009..Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib... - Lifetime recreational exercise activity and breast cancer risk among black women and white womenLeslie Bernstein
Department of Preventive Medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
J Natl Cancer Inst 97:1671-9. 2005.... - Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African AmericansFang Chen
Department of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Hum Mol Genet 20:4491-503. 2011..04, P = 6.1 × 10(-5)]. In this detailed analysis of the known breast cancer risk loci, we have validated and improved upon markers of risk that better characterize their association with breast cancer in women of African ancestry... - A variant in the cytochrome p450 oxidoreductase gene is associated with breast cancer risk in African AmericansChristopher A Haiman
Departments of Preventive Medicine and Pathology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
Cancer Res 67:3565-8. 2007..03) and stronger in those with advanced disease (411 cases and 877 controls; OR, 2.60; 95% CI, 1.56-4.34; P = 0.0002). These data suggest that African Americans harbor an allele at the POR locus that may increase breast cancer risk... - Receptor tyrosine kinase EphB4 is a survival factor in breast cancerS Ram Kumar
Department of Pathology, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, NOR 6330, Los Angeles, CA 90033, USA
Am J Pathol 169:279-93. 2006..Our data indicate that biologically active EphB4 functions as a survival factor in breast cancer and is a novel target for therapy... - Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targetingTove Olafsen
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 700 Westwood Plaza, Los Angeles, CA 90095, USA
Protein Eng Des Sel 17:315-23. 2004..62 h) was similar. Thus, minibodies with different specificities display similar pharmacokinetics, while tumor uptake may vary depending on the antigen-antibody system... - Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapyMichael F Press
Norris Comprehensive Cancer Center, University of Southern California, CA, USA
J Clin Oncol 29:859-67. 2011..This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers... - EGFR, HER2 and VEGF pathways: validated targets for cancer treatmentMichael F Press
Department of Pathology, Keck School of Medicine, Oncology, University of Southern California Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA
Drugs 67:2045-75. 2007..The results achieved with targeted therapies to date are promising, although they illustrate the need for additional preclinical and clinical study... - Antibody-mediated targeting of replication-competent retroviral vectorsChien-Kuo Tai
Institute for Genetic Medicine, Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
Hum Gene Ther 14:789-802. 2003..Application of antibody-mediated targeting to the initial localization of replication-competent virus vectors to tumor sites will thus require optimized target selection and vector design... - Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensMichael F Press
Breast Cancer Research Program of the Lee Breast Center, Department of Pathology, University of Southern California, Los Angeles, USA
J Clin Oncol 20:3095-105. 2002..To compare and evaluate HER-2/neu clinical assay methods... - P7 antigen expression in human breast cancerXiaowei Yang
Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles, California 90033, USA
Clin Cancer Res 9:201-6. 2003..The markedly increased expression in patients with locally advanced disease after neoadjuvant therapy suggests a role for p7 in treatment outcome... - Lifetime recreational exercise activity and risk of breast carcinoma in situAlpa V Patel
Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
Cancer 98:2161-9. 2003..02). CONCLUSIONS: The findings of the current study suggest that exercise activity may modify the risk of BCIS, particularly among women without a family history of breast carcinoma... - Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerDavid B Agus
Cedars Sinai Prostate Cancer Center and Medical Center, Los Angeles, CA 90048, USA
J Clin Oncol 23:2534-43. 2005..A clinical study was conducted to investigate safety and pharmacokinetics of pertuzumab and to perform a preliminary assessment of HER dimerization inhibition as a treatment strategy... - Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trialLinda Hovanessian-Larsen
Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Contraception 86:238-43. 2012.... - Identification of TP53 mutations in human cancers using oligonucleotide microarraysWen-Hsiang Wen
Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
Methods Mol Med 97:323-35. 2004 - Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumabRobert D Mass
Genentech, Inc, South San Francisco, CA 94080, USA
Clin Breast Cancer 6:240-6. 2005..CONCLUSION: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy... - The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational resultsPolly A Marchbanks
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Ann Epidemiol 12:213-21. 2002..5% and 78.6%, respectively, with lower rates for black women and older women. CONCLUSIONS: The methodologic details of this large collaboration may assist researchers conducting similar investigations... - Racial differences in the familial aggregation of breast cancer and other female cancersMichael S Simon
Division of Haematology and Oncology, Barbara Ann Karmanos Cancer Institute, 4100 John R, 4221 Hudson, Weber Cancer Research Building, Detroit, M1 48201, USA
Breast Cancer Res Treat 89:227-35. 2005..17 (1.22-3.85). In conclusion, these racially distinct aggregation patterns may reflect different modes of inheritance and/or environmental factors that impact cancer risk... - Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences StudyMichael S Simon
Division of Hematology and Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA
J Clin Oncol 24:2498-504. 2006..The purpose of this report is to update breast cancer risk estimates associated with a family history of breast cancer for white and AA women... - HER2 testing in breast cancer: NCCN Task Force report and recommendationsRobert W Carlson
Stanford Hospital and Clinics
J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed... - Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumabNoel Dybdal
Genentech Inc, South San Francisco, CA 94080, USA
Breast Cancer Res Treat 93:3-11. 2005..The IHC protocol used was a research assay, known as the Clinical Trial Assay (CTA), developed to select women with metastatic breast cancer (MBC) for three pivotal clinical trials of trastuzumab therapy... - Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerMark D Pegram
Oncology Research Network, David Geffen School of Medicine, and Division of Hematology/Oncology, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:759-69. 2004..The BCIRG is conducting ongoing randomized studies of the three-drug combination in both the metastatic and adjuvant settings... - Oral contraceptive use and risk of breast carcinoma in situ (United States)Jasmeet K Gill
Etiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA
Cancer Causes Control 17:1155-62. 2006..CONCLUSIONS: Our results are consistent with recent results on invasive breast cancer reported for the Women's Contraceptive and Reproductive Experiences Study and show no association between oral contraceptive use and risk of BCIS... - How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified?Michael F Press
Am J Clin Pathol 126:673-4. 2006 - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C Wolff
American Society of Clinical Oncology, Alexandria, VA, USA
J Clin Oncol 25:118-45. 2007..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker... - Timing of menarche and first full-term birth in relation to breast cancer riskChristopher I Li
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Am J Epidemiol 167:230-9. 2008..The authors conclude that the interval between age at menarche and age at first birth is associated with the risk of hormonally sensitive types of breast cancer, particularly among White women... - Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imagingTove Olafsen
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California at Los Angeles, 90095, USA
Cancer Res 65:5907-16. 2005..1 +/- 1.5% ID/g). Thus, by manipulating the size and format of anti-p185(HER2) antibody fragments, the kidney activity was reduced and high or low expression of p185HER2 in xenografts could be distinguished by microPET imaging... - Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancerChristopher I Li
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 C308, P O Box 19024, Seattle, WA 98109 1024, USA
Cancer Epidemiol Biomarkers Prev 15:946-54. 2006.... - Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'Marc E Lippman
Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI 48109-0368, USA
Breast Cancer Res Treat 90:1-3. 2005